Journal article
Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells
Ruian Ke, Sharon R Lewin, Julian H Elliott, Alan S Perelson
PLOS PATHOGENS | PUBLIC LIBRARY SCIENCE | Published : 2015
Grants
Awarded by U.S. Department of Energy
Awarded by NIH
Awarded by NHMRC
Awarded by National Institutes of Health Delaney AIDS Research Enterprise (DARE) to find a cure
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Awarded by OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH
Funding Acknowledgements
This work was performed under the auspices of the U.S. Department of Energy under contract DE-AC52-06NA25396 and supported by NIH grants R01-AI028433, R01-OD011095 and UM1-AI100645 (ASP). SRL is an NHMRC Practitioner Fellow. This work was also supported by NHMRC project grants # 4911954 and # 1002671 and the National Institutes of Health Delaney AIDS Research Enterprise (DARE) to find a cure U19 AI096109. The clinical study of vorinostat was supported in part by a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.